Can a simple blood test predict pancreatic cancer before it strikes?
NCT ID NCT04247503
First seen Jun 27, 2026 · Last updated Aug 06, 2026 · Updated 2 times
Summary
This study follows 419 people who do not have pancreatic cancer but are at high risk due to family history or genetic mutations. Researchers collect blood samples and health information over time to find markers that could predict or detect pancreatic cancer early. The goal is to improve early diagnosis and save lives.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
419 people
The number who actually took part.
- Started
-
Dec 2019
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Individuals aged 50 and older without pancreatic cancer who are members of kindreds containing three blood relatives with pancreatic cancer, OR who carry a mutation in a known predisposition gene for pancreatic cancer.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. An individual who has previously consented to the Biospecimen Resource for Pancreas Research (Substudy #2 Family Studies) - IRB 355-06 2. Individual who does not have a personal history of pancreatic cancer and meets one of the following: 1. Has relatives in family that contains pancreatic cancer, and carries a known germline mutation in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53. OR 2. Is a first- or second-degree blood relative of an individual with a diagnosis of pancreatic ductal adenocarcinoma (PDAC) and this PDAC patient has a germline mutation in APC, ATM, BRCA1, BRCA2, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, STK11, or TP53. OR 3. Is a first- or second-degree blood relative of an individual with a germline mutation in one of these genes and where the mutation carrier is also a first-degree relative to a PDAC case. OR 4. Is a blood relative to a PDAC patient in a family that contains three blood relatives (all maternal side or all paternal side) with PDAC. 3. Age 1. 50 or older, OR 2. Or within 10 years of the age of diagnosis of the youngest PDAC blood relative. 4. Individual with a valid United States mailing address. - Exclusion Criteria: 1. Individual who has a personal history of PDAC 2. Individual who has received a bone marrow transplant, who has had a blood transfusion within the last 7 days, or who has an active hematologic malignancy (i.e., leukemia or lymphoma). 3. Individual who is unable to sign the informed consent because of mental incompetency or psychiatric illness 4. Individual who is non-English speaking 5. Individual who is a prison inmate -
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Familial pancreatic cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
Rochester, Minnesota, 55902, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.